News - 02 Jul `20Vitiligo drug candidate goes to the finals of The Nature Spinoff Prize

New

Temprian Therapeutics, a spinoff from Northwestern University with patent for DNA-based vitiligo treatment, has made it to the finals of the Nature Spinoff Prize.

The 12 finalists represent companies from the United States, United Kingdom, Switzerland and Spain operating in pharmaceuticals, predictive assays and medical devices. Temprian’s selection as a finalist for the Nature Spinoff Prize provides hope for securing investment needed for a clinical trial. 

The judges will select four companies to participate in a live slam on 13 July. The winner will be awarded the title of 2020 Nature Spin-off Prize champion — and a grant of €30,000 (about US$34,000).

Details of Temprian’s innovation and its underlying patent Mutant HSP70i to Prevent Autoimmune Disease.

 



      FAQOther Questions

      • How long does it take to treat vitiligo?

        Vitiligo, a condition characterized by the loss of skin pigment, can be unpredictable in both progression and treatment. The time it takes to treat vitiligo varies significantly...

      • Who is prone to vitiligo?

        Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...

      • Shall I take vitamin D for my vitiligo?

        Vitamin D plays a central role in the prevention of different inflammatory and chronic diseases. Consuming 1,000–4,000 IU (25–100 mcg) of vitamin D3 daily should be ideal for mo...